What Is the Depo-Provera Lawsuit About?

Depo-Provera is the brand name for an injectable contraceptive containing medroxyprogesterone acetate (MPA), a synthetic progestin. Administered roughly every three months, it has been marketed in the United States since the 1990s — historically through Pharmacia & Upjohn and now under Pfizer — as a convenient alternative to daily oral contraceptives. The litigation centers on the related products Depo-Provera CI (the 150 mg intramuscular injection) and Depo-SubQ Provera 104 (a 104 mg subcutaneous version), along with authorized generics.

The core allegations are familiar to anyone who follows defective product liability claims: plaintiffs assert that Pfizer and related distributors knew, or reasonably should have known, that long-term exposure to MPA was associated with an elevated risk of intracranial meningioma, and that the companies failed to place an adequate warning on the U.S. label until December 2025. Complaints generally raise theories of failure to warn, negligence, defective design, and misrepresentation. Plaintiffs typically seek compensation for medical treatment, surgery, neurological injury, long-term disability, lost income, and pain and suffering.

In February 2025, the Judicial Panel on Multidistrict Litigation consolidated federal Depo-Provera cases into MDL 3140 — In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation — before the Honorable M. Casey Rodgers in the Northern District of Florida (Pensacola Division). Pfizer is the primary defendant; complaints also name affiliated entities such as Viatris, Greenstone, Prasco, and Pharmacia & Upjohn. The docket has expanded rapidly: court and panel filings show the case count climbing into the thousands through 2025 and 2026, making this one of the larger active pharmaceutical MDLs in the country.

The Science: Depo-Provera and Meningioma Risk

The scientific anchor of this litigation is a national case-control study by Roland and colleagues, published in The BMJ on March 27, 2024. Drawing on French national health data from 2009 to 2018 and a population of roughly 18,000 women who underwent surgery for intracranial meningioma, the researchers reported that prolonged use (one year or more) of injectable medroxyprogesterone acetate at the 150 mg dose was associated with an odds ratio of about 5.5 for intracranial meningioma — meaning the odds were several times higher among long-term users than among non-users.

That relative figure is striking, but responsible reporting requires context. The number of MPA-exposed cases in the French study was small, and the authors and independent commentators have emphasized that the absolute risk of meningioma in any individual remains low. Meningiomas are also frequently benign and slow-growing, though they can cause serious neurological effects — including headaches, vision changes, and seizures — when they press on nearby tissue, and may require surgery or radiation. Subsequent analyses, including work by Griffin and colleagues using U.S. insurance data, have likewise reported elevated associations, while raising methodological questions about latency and comparison groups. In short, the science describes a statistical association that is biologically plausible (meningiomas often express hormone receptors), but the strength and causal interpretation of that association remain subjects of active scientific and courtroom debate.

The regulatory landscape shifted in December 2025, when the U.S. Food and Drug Administration approved supplemental labeling that added meningioma information to the warnings and the patient-counseling sections of Depo-Provera CI and Depo-SubQ Provera 104. European regulators had moved earlier on related progestogens. For plaintiffs, the timing of the U.S. label change is central: claims generally concern the period before a meningioma warning existed on the American label. This article does not offer medical advice; anyone with health questions about a current or past prescription should speak with a licensed physician rather than make changes based on litigation news.

Who Qualifies — Full Eligibility Breakdown

Eligibility is determined case by case, and only a licensed attorney can evaluate a specific situation. That said, attorneys reviewing potential Depo-Provera claims generally look for three building blocks: documented use of the product, a confirmed meningioma diagnosis, and a consistent timeline connecting the two. Claimants who can document longer use — the BMJ analysis focused on a one-year-plus threshold — typically present stronger causation arguments, although shorter-use cases are still being investigated by some firms.

Plaintiffs generally need to show that the diagnosis is an intracranial meningioma (as opposed to another tumor type) and that it was identified through objective imaging or pathology. Attorneys often note that gaps in records — missing pharmacy histories, undocumented injection dates, or unclear diagnostic timelines — are among the most common reasons a potential claim is harder to pursue. The table below summarizes the criteria that claimants generally encounter.

Estimated Settlement Amounts

This is the question most readers arrive with, and it requires the firmest caveat: there is no global Depo-Provera settlement, and no court-approved compensation framework, as of mid-2026. Any dollar figure circulating online is a projection, not a promise. Such projections generally draw on how comparable pharmaceutical and product-liability mass torts have resolved, and they are heavily dependent on facts that have not yet occurred here — most importantly the outcomes of the early bellwether trials and the court’s rulings on causation and federal preemption.

When mass-tort matters do resolve, individual values are typically driven by injury severity and the strength of the supporting evidence. Factors attorneys commonly cite include whether the claimant required brain surgery, whether radiation was needed, whether there is a permanent neurological deficit (such as lasting vision loss or cognitive impairment), the documented duration of product use, the clarity of the diagnostic timeline, and economic losses such as medical bills and lost earnings. To understand how analysts arrive at tiered estimates, it helps to look at comparable mass-tort settlements and at how tiered mass-tort payouts are structured in other litigation — though every tort is distinct, and past results never guarantee future outcomes.

The tiers below reflect ranges that some analysts and plaintiff firms have speculatively projected for this litigation. They are presented for educational illustration only.

Statute of Limitations by State

A statute of limitations is the legal deadline for filing a lawsuit, and it is one of the most consequential — and most misunderstood — features of any injury claim. Miss it, and a court will usually dismiss the case no matter how strong the underlying facts are. For pharmaceutical injuries, the deadline is set by each state, and the clock often does not start on the day the drug was used. Instead, many states apply a “discovery rule,” under which the limitations period begins when a person knew, or reasonably should have known, that an injury may be connected to a particular product. In meningioma cases, that date can be debated — it may be tied to the diagnosis, to media or label developments, or to when a physician first raised a possible link.

Because these rules are state-specific and fact-sensitive, the examples below are illustrative only. They do not account for tolling, statutes of repose, minority or disability exceptions, or recent amendments, all of which can change the analysis. Plaintiffs generally consult a licensed attorney in their own state promptly rather than relying on a general chart.

The practical takeaway is consistent across states: deadlines are unforgiving, the discovery rule does not extend them indefinitely, and the safest course for anyone weighing a claim is to confirm the applicable date with counsel early.

MDL 3140 Timeline & Bellwether Trials

MDL 3140 is overseen by Judge M. Casey Rodgers, an experienced mass-tort jurist, in the Northern District of Florida. The court has moved the litigation along a structured pretrial path of case-management orders addressing leadership, “pilot” (bellwether) case selection, threshold proof-of-use and proof-of-injury requirements, and briefing on federal preemption. Coordinating thousands of individual cases this way is the hallmark of a multidistrict litigation, and it is a familiar structure across other pharmaceutical injury litigation.

Two dates dominate the near-term calendar. First, Daubert (Rule 702) hearings on general causation are scheduled for June 24–26, 2026. At these hearings the court evaluates whether the plaintiffs’ expert testimony linking MPA to meningioma is sufficiently reliable to reach a jury — a threshold that can shape, and in some torts effectively decide, the viability of the litigation. Second, the first bellwether trial is set to begin December 7, 2026, in the lead case widely identified as Blonski v. Pfizer. Bellwether trials are representative cases tried first; their verdicts do not bind other plaintiffs, but they give both sides real-world data on how juries weigh the evidence and value injuries. In mass torts, meaningful settlement negotiations frequently follow — rather than precede — these early results.

MDL vs Class Action — What’s the Difference?

The Depo-Provera litigation is regularly, and incorrectly, called a “class action.” It is a multidistrict litigation (MDL). The distinction matters for anyone trying to understand how compensation could work. Readers can review how an MDL differs from a class action in detail, but the essentials are as follows.

In a class action, many people with similar claims are combined into a single representative case; class members generally share one collective outcome and divide a common recovery, often with relatively uniform treatment. In an MDL, by contrast, federal cases that share common questions are transferred to one judge purely for coordinated pretrial proceedings — discovery, expert challenges, and bellwether trials — to promote efficiency and consistency. Crucially, each plaintiff keeps an individual lawsuit. If cases do not resolve collectively, they can be sent back to their home courts for trial, and any compensation is typically tied to that individual’s specific injuries and evidence rather than a single class-wide formula. This individualized structure is one reason analysts project tiered values rather than a flat per-person figure.

Evidence & How Claims Are Filed

The question of how to file a depo-provera claim ultimately turns on documentation. Attorneys generally explain that two categories of proof carry the most weight: proof of use and proof of injury. Proof of use commonly includes pharmacy records, insurance or billing records, immunization-style injection logs, and physician or clinic notes identifying Depo-Provera, Depo-SubQ Provera 104, or an authorized generic, along with the approximate dates and duration of use. Proof of injury generally includes MRI or CT imaging confirming an intracranial meningioma, the accompanying radiology report, and — where surgery occurred — operative and pathology reports.

From there, the mechanics are typically handled by counsel. After an intake review, attorneys often request records on the claimant’s behalf, evaluate the diagnostic and use timeline, confirm the applicable statute of limitations, and, where appropriate, file directly into MDL 3140 under the court’s direct-filing procedures or in an appropriate jurisdiction. Plaintiffs are generally also asked to complete a court-mandated fact sheet documenting their use and injury. Because intake standards and deadlines differ, claimants are usually advised to gather whatever records they already have and to consult an attorney rather than attempting to self-file a complex product-liability claim.

Pfizer’s Defense & the FDA Label Question

Pfizer has not conceded liability, and its defenses are substantial. The two most prominent are federal preemption and challenges to general causation. On preemption, Pfizer has argued that it could not have unilaterally added a meningioma warning to the U.S. label earlier because, under the relevant regulatory framework, the FDA controls label content — and the company has contended that a proposed change was not approved on the timeline plaintiffs assert, with the agency ultimately approving the meningioma label update in December 2025. If a court accepts a preemption argument, it can bar some claims regardless of their factual merits, which is why a pending preemption ruling is being watched closely.

On causation, the defense is expected to argue at the June 2026 Daubert hearings that the epidemiological evidence — including the limited number of MPA-exposed cases in the 2024 BMJ study and questions about latency and comparison groups — does not reliably establish that Depo-Provera causes meningioma, as opposed to being statistically associated with it. Plaintiffs counter that the body of evidence, the biological plausibility of hormone-driven tumor growth, and the eventual label change support their position. How the court resolves these issues will significantly influence the litigation’s trajectory.

What Happens Next

The next six to twelve months are likely to be decisive. The Daubert ruling expected after the June 2026 hearings will clarify whether plaintiffs’ causation experts can testify, and the December 2026 bellwether trial will produce the first jury data points on liability and damages. A pending preemption decision could narrow or reshape the pool of viable claims. Strong plaintiff verdicts would generally increase settlement pressure; favorable defense rulings could do the opposite. Observers often compare this trajectory to similar claims over women’s health products, where early rulings and bellwether outcomes heavily influenced whether and how the parties moved toward resolution.

For now, the litigation remains in pretrial proceedings, new filings continue, and no compensation is guaranteed to anyone. Claimants generally use this window to preserve records, confirm deadlines, and obtain individualized legal advice, while watching the court’s rulings as the bellwether process unfolds.

Key Terms in the Depo-Provera Litigation

Meningioma

A tumor that forms in the meninges, the protective membranes surrounding the brain and spinal cord. Meningiomas are frequently benign but can cause serious symptoms — such as headaches, vision changes, or seizures — when they grow large enough to press on nearby structures.

Medroxyprogesterone acetate (MPA)

The synthetic progestin that is the active ingredient in Depo-Provera. The litigation centers on whether long-term exposure to MPA is associated with an increased risk of intracranial meningioma.

Multidistrict litigation (MDL)

A federal procedure that transfers many separate lawsuits sharing common questions to a single judge for coordinated pretrial proceedings. Unlike a class action, each plaintiff keeps an individual case.

Bellwether trial

A representative early trial used to test how juries respond to the evidence and to gauge case values. The results are not binding on other plaintiffs but often guide settlement discussions.

Daubert (Rule 702) hearing

A proceeding in which the court evaluates whether expert testimony — here, the science linking MPA to meningioma — is reliable enough to be presented to a jury.

Federal preemption

A defense argument that federal law, such as FDA control over drug labeling, overrides certain state-law claims. If accepted, it can bar some claims regardless of their underlying facts.

Statute of limitations

The legal deadline for filing a lawsuit. In many states a “discovery rule” can delay the start of the clock until a person reasonably connects their injury to the product.

Key Takeaways

The Depo-Provera meningioma litigation — sometimes called the Depo shot brain tumor lawsuit — is large, active, and still in its early stages. The essentials worth remembering:

• The science describes an association, not a settled verdict. The 2024 BMJ study linked long-term medroxyprogesterone acetate use to higher meningioma odds, but the absolute risk is low and causation remains contested — which is precisely what the June 2026 Daubert hearings are meant to resolve.
• The regulatory turning point was December 2025, when the FDA added meningioma information to the U.S. Depo-Provera label.
• It is an MDL, not a class action. Cases are consolidated in MDL 3140 before Judge M. Casey Rodgers, yet each plaintiff keeps an individual claim and an injury-specific potential recovery.
• No settlement exists and no figure is guaranteed. Projected payout tiers are speculative estimates that hinge on the December 2026 bellwether trial and the court’s rulings on causation and preemption.
• Deadlines vary sharply by state and can bar a claim regardless of its strength, so Depo-Provera lawsuit eligibility is best confirmed with counsel promptly.

Anyone weighing a claim is best served by speaking with a licensed attorney in their state, and by consulting a physician for any medical questions rather than acting on litigation news alone.

This article is for general informational and educational purposes only and does not constitute legal or medical advice. It does not create an attorney-client relationship. No outcome, settlement amount, or eligibility determination is guaranteed; all figures referenced are estimates and not promises of compensation. Litigation status changes frequently. Anyone considering a claim should consult a licensed attorney in their state. Sources: U.S. Courts (MDL 3140), U.S. FDA, and peer-reviewed medical research.